Assess the Efficacy/Safety of Intravitreal Ranibizumab in Patients With Vision Loss Due to Choroidal Neovascularization.
Status:
Completed
Trial end date:
2015-11-01
Target enrollment:
Participant gender:
Summary
This study was conducted to evaluate the efficacy and safety of 0.5 mg ranibizumab in adult
and adolescent patients with visual impairment due to choridal neovascularization (CNV).